Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WG105
- Development stage
- Preclinical
- Lead developer
- Shenzhen Wingor Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
WG105 is a preclinical-stage stem cell therapy being developed by Shenzhen Wingor Biotechnology. It is part of a pipeline of cellular drugs aimed at treating a variety of conditions, including neoplasms (cancers) and immune system diseases. As a stem cell-based product, it likely leverages the regenerative or immunomodulatory properties of stem cells, though the specific cell type and exact mechanism of action have not been publicly disclosed. The drug is currently in the early stages of research and development within the company's broader portfolio of stem cell, exosome, and immune cell technologies.
Beyond the preview
Go deeper on WG105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WG105.